CRINETICS PHARM (CRNX)
(Delayed Data from NSDQ)
$33.91 USD
-1.57 (-4.43%)
Updated Sep 19, 2025 04:00 PM ET
After-Market: $34.01 +0.10 (0.29%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
CRNX 33.91 -1.57(-4.43%)
Will CRNX be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for CRNX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CRNX
Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q2 Loss, Lags Revenue Estimates
Earnings Preview: Crinetics Pharmaceuticals, Inc. (CRNX) Q2 Earnings Expected to Decline
CRNX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Ionis Pharmaceuticals (IONS) Moves 9.1% Higher: Will This Strength Last?
Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q1 Loss, Tops Revenue Estimates
Esperion Therapeutics (ESPR) Reports Q3 Loss, Lags Revenue Estimates
Other News for CRNX
20 Day Moving Average Support appears for CRNX after 4.43% move
Interesting CRNX Put And Call Options For November 21st
CRNX forms MACD Bullish Signal Line Cross on September 19
Is CRNX positioned for a breakdown? MACD Bearish Signal Line Cross shows up after gaining 0.29%
The technical outlook for CRNX is unchanged after it rises 0.98% on September 16